Standard 30-minute Monitoring Time and Less Intensive Pre-medications is Safe in Patients Treated With Subcutaneous Daratumumab for Multiple Myeloma and Light Chain Amyloidosis

Clin Lymphoma Myeloma Leuk. 2022 Aug;22(8):566-568. doi: 10.1016/j.clml.2022.03.003. Epub 2022 Mar 9.
No abstract available

Publication types

  • Editorial

MeSH terms

  • Amyloidosis* / drug therapy
  • Antibodies, Monoclonal / adverse effects
  • Humans
  • Immunoglobulin Light-chain Amyloidosis* / diagnosis
  • Immunoglobulin Light-chain Amyloidosis* / drug therapy
  • Multiple Myeloma* / drug therapy

Substances

  • Antibodies, Monoclonal
  • daratumumab